Significantly fewer (P < 0.05) epoetin α-treated patients experienced anaemia (Hb < 10 g dl−1) during the course of chemotherapy (300 IU kg−1, 39%; 150 IU kg−1, 48%; untreated, 66%). Here, EPO is linked to anemia.